Seeking Alpha·Jun 25, 2026
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call TranscriptAddex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Transcript
Addex Therapeutics Ltd(ADXN)Earnings, Financials & Key Ratios
ADXN•NASDAQ
$6.00
Price updated Jul 7, 2026
AboutAddex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.Show more
- Revenue$30K-92.6%
- EBITDA-$3M-12.5%
- Net Income-$7M-195.4%
- EPS (Diluted)-6.88-181.9%
- Gross Margin100%
- EBITDA Margin-9362.49%-1416.3%
- Operating Margin-9390.76%-1277.3%
- Net Margin-22448.44%-1385.7%
- ROE-93.16%-171.4%
ADXN Price & Volume
Addex Therapeutics Ltd (ADXN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Milestone Dependence Threatens Corporate Liquidity Viability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Critical liquidity and funding
Key Thesis Takeaways
- Addex Therapeutics faces a precarious outlook as its reliance on sporadic milestone payments has failed to offset a persistent, high fixed-cost structure, leading to a significant erosion of shareholder equity from $12.7 million in 2024Q2 to $3.3 million by 2026Q1.
- The company's inability to achieve operational self-sufficiency, evidenced by a 2026Q1 net margin of -209.3%, suggests that future clinical development will likely require highly dilutive financing.
- Investors should monitor the company's critical liquidity threshold, as the current cash position of $935.2K is insufficient to support long-term research and development activities.
Verdict Logic
the company's precarious liquidity position, evidenced by a current ratio of 0.97 and a cash balance of only $935.2K, suggests a high probability of near-term dilutive capital raises.
ADXN Growth Metrics
Addex Therapeutics Ltd (ADXN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-2.92%
5 Years-61.65%
3 Years-72.38%
TTM-56.51%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-180.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-165.23%
Return on Capital
10 Years-102.95%
5 Years-66.01%
3 Years-50.43%
Last Year-37.42%
ADXN Recent Earnings
Addex Therapeutics Ltd (ADXN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 1/12 qtrs (10%)●Beat Revenue 3/12 qtrs (30%)
Q3 2026Latest
Jun 25, 2026Metric
Actual
Est
EPS
$1.48
—
Rev
$9,836
—
Q2 2026
Apr 30, 2026Metric
Actual
Est
EPS
$1.94-36.0%
$1.42
Rev
$313,000+32.3%
$236,616
Q4 2025
Dec 4, 2025Metric
Actual
Est
EPS
$1.50
—
Rev
$37,364-84.2%
$236,616
Q3 2025
Jun 20, 2025Metric
Actual
Est
EPS
$1.33+68.8%
$4.26
Rev
—
$236,616
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q3 2026Latest | Jun 25, 2026 | $1.48 | $9,836 |
| Q2 2026 | Apr 30, 2026 | $1.94vs $1.42-36.0% | $313,000vs $236,616+32.3% |
| Q4 2025 | Dec 4, 2025 | $1.50 | $37,364vs $236,616-84.2% |
| Q3 2025 | Jun 20, 2025 | $1.33vs $4.26+68.8% | —vs $236,616 |
Based on last 12 quarters of dataView full earnings history →
Latest ADXN News
Recent stock market news and headlines for Addex Therapeutics Ltd (ADXN)
GlobeNewsWire·Jun 25, 2026
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateAd Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its Q1 2026 financial results and provided a corporate update.
GlobeNewsWire·Jun 22, 2026
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its First Quarter 2026 Financial Results on June 25, 2026. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on June 25, 2026.
Peers Comparison
Key metrics vs top competitors for Addex Therapeutics Ltd (ADXN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.00 | $4.32M | -0.70 | -92.58% | -22448.44% | -93.16% | — | |
| $26.20 | $4.49B | 11.44 | 11.87% | 34.3% | 35.65% | — | |
| $22.25 | $1.64B | 6.74 | 18.52% | 118.91% | 47.59% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $177.49 | $17.81B | 38.01 | 21.45% | 21.55% | 21.64% | — | |
| $1.32 | $63.77M | -2.54 | — | — | -95.77% | — |
Compare ADXN vs Peers
Addex Therapeutics Ltd (ADXN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ADXN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ADXN Frequently Asked Questions
Addex Therapeutics Ltd (ADXN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Addex Therapeutics Ltd's revenue?
Addex Therapeutics Ltd (ADXN) reported $0.1M in revenue for fiscal year 2025. This represents a 98% decrease from $4.7M in 2006.
How fast is Addex Therapeutics Ltd growing?
Addex Therapeutics Ltd (ADXN) saw revenue decline by 92.6% over the past year.
Is ADXN profitable?
Addex Therapeutics Ltd (ADXN) reported a net loss of $7.0M for fiscal year 2025.
Dividend & Returns
What is ADXN's return on equity?
Addex Therapeutics Ltd (ADXN) has a return on equity (ROE) of -93.2%. Negative ROE indicates the company is unprofitable.
What is Addex Therapeutics Ltd's free cash flow?
Addex Therapeutics Ltd (ADXN) had negative free cash flow of $2.3M in fiscal year 2025, likely due to heavy capital investments.